What is B. Riley's Forecast for Agenus FY2024 Earnings?

Agenus Inc. (NASDAQ:AGEN - Free Report) - Analysts at B. Riley decreased their FY2024 EPS estimates for shares of Agenus in a report issued on Monday, November 18th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of ($10.51) per share for the year, down from their previous forecast of ($6.27). B. Riley currently has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Agenus' current full-year earnings is ($6.27) per share. B. Riley also issued estimates for Agenus' Q4 2024 earnings at ($1.56) EPS, Q1 2025 earnings at ($2.13) EPS, Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($2.07) EPS, FY2025 earnings at ($5.83) EPS, FY2026 earnings at ($8.68) EPS, FY2027 earnings at ($7.86) EPS and FY2028 earnings at ($2.20) EPS.

Several other equities research analysts have also recently issued reports on AGEN. HC Wainwright lowered their price objective on Agenus from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Tuesday, November 12th. StockNews.com lowered shares of Agenus from a "hold" rating to a "sell" rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $10.00.

Agenus Stock Up 4.7 %

Shares of Agenus stock traded up $0.12 on Wednesday, reaching $2.69. The company's stock had a trading volume of 351,254 shares, compared to its average volume of 648,725. Agenus has a 52-week low of $2.50 and a 52-week high of $19.69. The company has a market capitalization of $63.11 million, a P/E ratio of -0.25 and a beta of 1.39. The stock has a 50-day moving average price of $4.59 and a 200-day moving average price of $8.50.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in shares of Agenus by 81.3% during the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company's stock valued at $109,000 after buying an additional 84,477 shares during the period. Vanguard Group Inc. increased its position in shares of Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company's stock worth $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Agenus by 1,959.9% in the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company's stock valued at $439,000 after buying an additional 720,629 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company's stock valued at $208,000 after buying an additional 123,058 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in Agenus during the second quarter worth about $1,921,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.